A lthough smoking rates have declined in the United States, lung cancer continues to be a pandemic. 1 It is the number one cause of cancer related deaths world-wide. In 2006 there were an estimated 174,000 patients diagnosed with lung cancer and 162,000 deaths due to lung cancer in the United States alone. 1 Bronchogenic malignancy has been shown in large registry databases to have racial disparity in clinicopathologic characteristics and in survival. However, these databases feature inconsistent staging, many different treating physicians, and multiple treatment strategies and a whole host of other confounders.
Advances in genetics and the social sciences have demonstrated that race, in and of itself, is usually not a relevant biologic factor; rather it is a complex variable heavily impacted by strong socioeconomic associations. 2 Mortality from lung cancer still remains highest in the African American population. [3] [4] [5] Given the striking differences in survival between patients with early stage lung cancer who undergo surgical resection and those who have alternative treatments, it is not surprising that research has shown that some of the higher mortality in African Americans with early stage non-small cell lung cancer (NSCLC) may be attributed to differences in surgical rates. 4 These rates are affected by stage, lead time bias, access to healthcare, and patient's and physician's attitude towards surgery, chemotherapy and radiation. Therefore, we attempted to minimize these effects. The goal of this study was to assess the survival difference between African American and White patients with NSCLC who received comparable staging tests and procedures and similar treatment. In addition, we attempted to control for the effect that socioeconomic status and access to health care might play.
METHODS

Study Design and Definitions
This study evaluates a consecutive cohort of patients with biopsy proven NSCLC, all pathologically staged using a similar algorithm by one physician. Patients were enrolled and followed from January 1997 to January 2007. Patients were excluded if they were 19 years of age or younger, had histology that was not NSCLC, or if they received neoadjuvant chemoradiotherapy without biopsy proven N2 disease. The University of Alabama at Birmingham's institutional review board approved this study and the prospective database used to collect the data. Patient consent was obtained for entry into the prospective database. This consent advised patients that the information in the prospective database may be used for future research.
The socioeconomic status of each patient was determined by using patients per capita annual income (selfreported), health insurance status (verified), and highest educational achievement (self-reported). Median per capita income was calculated by taking the patients average annual household income divided by the number of persons residing in the household. Health insurance status was stratified into four categories: patients with Medicare with a private secondary insurance company, any Health Maintenance Organization, or those covered by any private company were labeled as "privately insured", patients with Medicare only were labeled as "Medicare insured", patients with Medicaid only were labeled as Medicaid insured, and those with no insurance were classified as "uninsured." Highest educational achievement was self-reported and separated into the following categories: some high school but did not graduate, graduated high school or received General Educational Development, 2-year college (some college or associates degree), graduated 4-year college, masters or equivalent graduate level degree, and doctorate level degree. Time interval until patient presented to specialist was counted as the number of days between first abnormal chest radiograph to the date the patient initially presented to a pulmonologist, oncologist or thoracic surgeon.
Preoperative Staging
All patients were clinically staged using 5 mm collimated computed tomography (CT scan) of the chest and upper abdomen and in addition all patients underwent dedicated positron emission tomography (PET) using 2-dexoy-2-18F -flouro-D-glucose F-18 (FDG-PET or PET/CT) scan. Pathologic staging was required for inclusion into this study. All suspicious mediastinal nodes (N2 and/or N3) with a maximum SUV (maxSUV) Ն2.5 on FDG-PET scan or Ն1 cm in greatest axis on CT scan were biopsied before pulmonary resection. Mediastinoscopy and/or endoscopic ultrasound fine needle aspirate were used to biopsy different nodal stations as previously described. 6 All suspicious metastatic (M1) sites by FDG-PET or by CT scan were also investigated and/or biopsied. Patients with suspected M1 disease in the liver, adrenal, or contralateral lung underwent definitive biopsy to prove or disprove M1 cancer. If the bone or brain was suspected to harbor metastases, magnetic resonance imaging was considered the standard reference. The tumor, node, metastasis pathologic stage was assigned using the international staging system. 7
Treatment Strategy
In general, patients with stage I and II disease underwent resection through thoracotomy with complete thoracic lymphadenectomy. Those with biopsy-proven stage IIIa disease because of metastasis lymph node involvement proving N2 disease underwent platinum based chemotherapy with concurrent radiotherapy (chemo-radiotherapy). Selected patients with stage IV disease who underwent complete resection (some with a single brain metastasis and others with unsuspected M1 nodules in the same lung) were included in this study and were labeled as stage IV disease but were completely resected.
Patients who had biopsy proven N2 disease underwent platinum based chemoradiotherapy (using 4500 -6600 cGy) and were restaged with a chest CT and dedicated PET or PET/CT scans. If they were N2 negative after the completion of their neo-adjuvant therapy, they underwent resection. If a patient had biopsy proven N3 or M1 disease they were treated with additional chemoradiotherapy and not resected. Patients who were N2 negative underwent thoracotomy with complete resection. At thoracotomy, a complete thoracic lymphadenectomy (not nodal sampling) was used exclusively. Pathologic review was performed by means of standard techniques, immuno-histochemical staining, and marker testing were employed when appropriate.
Statistical Analysis
Continuous data are presented as medians and categorical data are presented as percentages. Characteristics of the patients and treatments were compared by Fisher exact test or Pearson's 2 test for categorical data and by the Wilcoxon test for continuous data. Survival estimates were derived by Kaplan-Meier analysis and log-rank test were used to assess differences in survival among the groups. Stratified log-rank analyses and Cox proportional-hazards modeling were used to investigate and adjust for major prognostic and stratification factors. Variables with p values Ͻ0.10 in univariate analysis were included in the step wise multivariate model. A two-sided p value of Ͻ0.05 was considered statistically significant. Patients alive at the end of the study period were censored for purposes of data analysis. Analysis was performed using the SAS software v. 9.0.
Data Collection and Follow-up
Patients were actively followed after pathologic staging and treatment to the end of this study. For patients who were completely resected, follow-up consisted of chest and abdominal CT scan every 6 months for the first 2 years and yearly afterward. Patients who were not completely resected underwent more frequent follow-up with their onocologist and/or surgical oncologist. Outcomes and follow-up data was obtained from multiple sources such as: clinic letters, follow-up scans, hospital computer information systems, tumor registry, social security death index, telephone calls, and letters from oncologists and other physicians. The time to disease recurrence (defined as biopsy-proven NSCLC), progression or death due to lung cancer was recorded. All information was entered into our prospective database. Data acquisition for new patients was stopped on January 2007 for this study but patient follow-up continued until March 2007.
performance status, and treatment. Patient demographics, preoperative, and socioeconomic characteristics are shown in Table 1 . Smoking history, per capita annual income, time to presentation, and health insurance type differed significantly between the two groups (p Ͻ 0.001, p ϭ 0.016, p ϭ 0.023 and p ϭ 0.008 respectively). Table 2 shows the operative and pathologic characteristics of African Americans and Whites. There was no significant difference in the histology and stage between the two groups. Figure 1 shows the proportion of patients who received neo-adjuvant therapy for preoperative mediastinal (N2) disease and their survival rates. Seventeen percent of African Americans declined neo-adjuvant therapy as compared with only 2% of Whites; this difference was statistically significantly different (p Ͻ 0.001). Among the patients that did receive neo-adjuvant therapy, the 5-year and 7-year survivals were similar for African Americans and Whites (p ϭ 0.10).
Survival Analysis
Kaplan-Meier analysis showed socioeconomic status (annual per capita income, insurance status, and education level) and time until presentation for treatment to be predictors of survival. Figure 2 shows that Whites had a greater overall 7-year survival than African Americans, however, this difference was not statistically significant (23% for Whites compare with 18% for African Americans, p ϭ 0.15). Cox Hazards regression analysis showed that annual per capita income (p ϭ 0.031) and time until presentation (p ϭ 0.002) were independent predictors of survival.
Stage specific Kaplan-Meier survival analysis showed that White patients had a significantly greater 5-year survival than African American patients for stages I, II and III NSCLC. Smoking rate significantly impacted all three stages, however, per capita income and time until presentation for treatment impacted survival in patients with early stage NSCLC only (stages I and II). Because the majority of patients with stage III disease were stage IIIA from N2 disease, we further analyzed the stage IIIa patients who had N2 disease by controlling for neo-adjuvant chemoradiotherapy and found no statistically significant difference in the 7-year survival rates between African Americans and Whites.
Gender specific Kaplan-Meier analysis showed no significant difference in survival rates of African American women and White women (p ϭ 0.181). Among men however, White men had a higher 7-year survival rate compared with African American men (31% compared with 18%, p ϭ 0.008). Smoking rate and time until presentation for treatment were the only independent predictors on Cox Hazards analysis (p ϭ 0.007) for African American men. Median follow-up period was 4.8 years (range, 2 months-10.1 year). Seventy-three (8%) patients were lost to follow-up.
DISCUSSION
Lung cancer is the number one cause of cancer deaths world-wide and there may be genetic, biologic, and/or epidemiologic factors that lead to different survival rates in subgroups of patients. For example, women are more likely to develop adenocarcinoma and have a better 5-year survival than men. 8 -12 This is true even when patients are carefully pathologically staged and completely resected. 13 Likewise, previous reports have suggested that race also plays an important factor in the survival of patients with NSCLC. Possible genetic factors have been presented to explain the poor survival of African Americans patients compared with White patients. Perez-Stable in 1998 reported a higher prevalence of genetic polymorphisms in African Americans compared with Whites. 14 They observed that African American smokers had a higher serum level of cotinine despite similar daily cigarette consumption and a 30% higher intake of nicotine per cigarette than Whites. Smoking patterns that vary by race may also account for some of these reported survival discrepancies. Although African American smokers seem to begin smoking at a later age, they are less likely to quit once started. In 1987, the quit rate for African American smokers was 32% as compared with 47% for White smokers. 15 Additionally, Cummings in 1987 reported an increased use of mentholated cigarettes in African Amer-icans (70 -80%) as compared with Whites (20 -30%). 16 Mentholated cigarettes have a higher tar content, 17 higher levels of carcinogens, 18 facilitate the absorption of carbon monoxide and decrease ventilation leading to greater pulmonary retention of tobacco smoke. Hence because of these reports and our practice that employs consistent, careful clinical, and pathologic staging of all patients and life-time follow-up, we decided to prospectively evaluate the impact of epidemiological and socioeconomic variables on survival rates for our patients with NSCLC. 19 In this study we found no significant difference in the survival of White patients compared with African American patients once we controlled for socioeconomic status variables and time until presentation for treatment. Smoking rates impacted survival only in men. Additionally, African Americans were more likely to refuse preoperative chemo-radiotherapy compared with Whites. Thus our data suggests that the difference in survival between White and African Americans is not genetic or biologic but rather may be related to access to health care and/or the patient's perception of healthcare and of various treatments.
In our report, African Americans were less likely to agree to neo-adjuvant chemo-radiotherapy for N2 disease, despite the recommendations for both groups to be the same. Earle in 2000 reported that there was wide variation in the utilization of palliative chemotherapy among Medicare patients, and nonmedical factors were strong predictors of whether a patient received chemotherapy or not. 20 Other factors that may influence type of treatment are patient perception, racial and cultural differences, expense, logistical issues, and performance status. Thus when we when controlled for socioeconomic status variables the survival gap between African Americans and Whites narrowed considerably. Although this type of study cannot be performed using the Surveillance, Epidemiological, End-Results database (because of inconsistent staging and treatment strategies and lack of smoking history data), previous reports using Surveillance, Epidemiological, End-Results have shown that most African American cancer patients live in high density areas with lower median income. The strengths of our study include that all patients were treated by one physician, patients come from similar geographic regions, received a dedicated PET or PET/CT before surgery, availability of socioeconomic data (income, educational level) and those who underwent surgery received a complete thoracic lymphadenectomy. Additionally, we were able to assess temporal differences in presentation for treatment between the groups. In a Veterans Administration study evaluating outcomes of patients with NSCLC or colon cancer, the survival of African Americans was equivalent to Whites, suggesting that equal access to comparable health care results in equal outcomes. 21 All of these facts limit confounding and stage migration. We also sought to eliminate known confounders of survival by matching on some of these characteristics. For example, we matched on performance status, comorbidities, and age. Age has been found to be a predictor for treatment choices--elderly patients have been found to be less accepting of potentially curative surgical treatments for difference cancers including early stage NSCLC. 19, 22 Limitations of this study include that it is uniinstitutional. Additionally, measurements of factors such as personal beliefs, surgical acceptance, racial and cultural differences cannot be objectively measured.
In conclusion, we found that White patients had better survival than African American patients overall and for stage I, II and III NSCLC on univariate analysis. However, when we adjusted for socioeconomic status and time to access to care, the racial disparity faded and the advantage was lost for those with early stage lung cancer (stages I or II). When we adjusted for neo-adjuvant therapy rates for stage IIIA disease, the survival advantage for stage III disease also disappeared.
Smoking only impacted survival in African American men. These data suggest the difference in survival between African American and White patients may not be genetic or biologic, but rather socioeconomic. Increased education and more prompt healthcare access may improve the dismal survival for patients with non-small cell lung cancer, in particular African American patients.
